Global Liver Metastases Treatment Market Size study & Forecast, by Type (Chemotherapy, Immunotherapy, Targeted Therapy) by Primary Cancer (Colorectal, Breast), by Distribution Channel (Hospital Pharmacies, Specialty Pharmacies) and Regional Analysis, 2022

Global Liver Metastases Treatment Market Size study & Forecast, by Type (Chemotherapy, Immunotherapy, Targeted Therapy) by Primary Cancer (Colorectal, Breast), by Distribution Channel (Hospital Pharmacies, Specialty Pharmacies) and Regional Analysis, 2022-2029

Global Liver Metastases Treatment Market is valued at approximately USD 1.2 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 7.2% over the forecast period 2022-2029. Liver Metastases are spread from an original Tumor or cancer to the liver. Liver Metastases do not begin with the Liver, they spread from other affected body parts. Cancers that spread to the liver cause Liver Metastases. Liver Metastases Treatment is the method used to cure Liver Metastases. Some of the common cancers that spread to the liver are breast cancer, colorectal cancer, esophageal cancer, and lung cancer. Increasing cases of breast and colorectal cancer, increasing government support and initiatives in cancer treatment, growing research and development, and rising incidence of target disease are the factors driving the growth of the market.

According to the World Cancer Research Fund, the global number of breast cancer cases was around 12.5% in the year 2020, whereas Lung cancer cases were around 12.2% in the same year. With 1.9 million new cases in 2020, colorectal cancer ranked third among all cancer types and accounted for 10.7% of all cases. Additionally, World Health Organisation unveiled a new global breast cancer initiative framework in February 2023, to achieve the goal of preventing 2.5 million deaths from breast cancer by 2040. The increasing cases of breast and colorectal cancer and increasing government support and initiatives are the major factors driving the growth of the market. Other important components driving market increase are growing research and development and the rising incidence of the target disease. Technological advancements in Liver Metastases Treatment and increasing R&D in healthcare are creating major market opportunities in the forecast period. However, the high cost of Liver Metastases Treatment stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Liver Metastases Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the availability of advanced treatment options for cancer, favorable government policies for cancer, and the high prevalence of liver metastases in the country such as the US. For instance, there are around 140,000 liver metastases cases annually in the US. Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as increasing healthcare expenditure, easy access to healthcare facilities, and lack of effective screening practices in the region.

Major market player included in this report are:
F. Hoffmann - La Roche Ltd.
AstraZeneca
Bayer AG
Eli Lilly and Company
Ono Pharmaceutical
Pfizer, Inc.
Bristol - Myers Squibb Company
Cadila Pharmaceuticals Ltd.
Biocare Medical, LLC
Foundation Medicine, Inc.
Recent Developments in the Market:
In March 2020, Nivolumab and ipilimumab were given rapid approval by the Food and Drug Administration to Ono Pharmaceuticals for the treatment of patients with hepatocellular carcinoma (HCC) who had previously been diagnosed with sorafenib.
In May 2020, atezolizumab and bevacizumab have been given FDA approval for the treatment of adult patients with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC) who have not had any prior systemic therapy.
Global Liver Metastases Treatment Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Type, Primary Cancer, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Type offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
Chemotherapy
Targeted Therapy
Immunotherapy

By Primary Cancer:
Colorectal Cancer
Breast Cancer

By Distribution Channel:
Hospital Pharmacies
Specialty Pharmacies

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the WorldCompanies Mentioned
F. Hoffmann - La Roche Ltd.
AstraZeneca
Bayer AG
Eli Lilly and Company
Ono Pharmaceutical
Pfizer, Inc.
Bristol - Myers Squibb Company
Cadila Pharmaceuticals Ltd.
Biocare Medical, LLC
Foundation Medicine, Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.